Bourin Michel
Neurobiology of Anxiety and Depression, Faculty of Medicine, Nantes, France.
Hum Psychopharmacol. 2003 Apr;18(3):185-90. doi: 10.1002/hup.467.
Paroxetine is a potent selective serotonin reuptake inhibitor (SSRI) with indications for the treatment of depression, obsessive- compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder and chronic headache. There is wide interindividual variation in the pharmacokinetics of paroxetine in adults as well as in the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment, however, serious adverse events are extremely rare even in overdose. A Pub Med search was used to collect information on the efficacy and tolerability in elderly patients. There are few studies of depression in the elderly and only one study in the old-old. In anxiety disorders including general anxiety disorder, panic disorder, obsessive-compulsive disorder and social anxiety, there are no studies at all in the elderly. However, the safety of the drug allows its prescription in the elderly. In summary, paroxetine is well tolerated in the treatment of depression in those between the ages of 65 and 75, although few studies have examined its use in those of 75 and older.
帕罗西汀是一种强效的选择性5-羟色胺再摄取抑制剂(SSRI),适用于治疗抑郁症、强迫症、恐慌症和社交恐惧症。它还用于治疗广泛性焦虑症、创伤后应激障碍、经前烦躁障碍和慢性头痛。帕罗西汀在成年人以及老年人中的药代动力学存在很大的个体差异,后者的血浆浓度较高且消除较慢。严重肾损伤和肝损伤时消除也会减少,然而,即使过量服用,严重不良事件也极为罕见。通过PubMed检索收集老年患者疗效和耐受性的信息。关于老年人抑郁症的研究很少,百岁老人的研究仅有一项。在包括广泛性焦虑症、恐慌症、强迫症和社交焦虑症在内的焦虑症方面,老年患者根本没有相关研究。然而,该药物的安全性使其可用于老年患者的处方。总之,帕罗西汀在65至75岁人群中治疗抑郁症时耐受性良好,不过很少有研究考察其在75岁及以上人群中的使用情况。